Myocardial Ischemia D017202

Diseases [C] » Cardiovascular Diseases [C14] » Heart Diseases » Myocardial Ischemia

Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Myocardial Ischemia

Description

A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).   MeSH

Hierarchy View

Subtype Terms (6)

Acute Coronary Syndrome
145 drugs (99 approved, 46 experimental)

Angina Pectoris
98 drugs (56 approved, 42 experimental)

Coronary Disease
245 drugs (150 approved, 95 experimental)

Kounis Syndrome
 

Myocardial Infarction
296 drugs (174 approved, 122 experimental)

Myocardial Reperfusion Injury
23 drugs (18 approved, 5 experimental)



Organization Involved with Phase 4 Indications (246)

Aalborg University

Aarhus University

Abant Izzet Baysal University

Abbott

Ada and Hagbart Waages Humanitarian and Charity Foundation

Aichi Gakuin University

Ajou University

Alf and Aagot Helgesens Research Foundation

Ankara Yildirim Beyazıt University

ANKON Medical Technologies

ANMCO Italian Association of Hospital Cardiologist

Aristotle University of Thessaloniki

Associations for Establishment of Evidence in Interventions

Astellas

AstraZeneca

Atlanta Heart Specialists, LLC

Aventis

Azienda Ospedaliera di Lecco

Bayer

Beijing Anzhen Hospital

Bio-Inova Life Sciences International

Boehringer Ingelheim

Boston Scientific Corporation

Bristol-Myers Squibb

British Heart Foundation

Campus Bio-Medico University

Capital Medical University

Cardiovascular Institute of the South Clinical Research Corporation

CardioVascular Research Foundation, Korea

Catholic University of Korea

CCRF Consulting Co., Ltd.

Cedars-Sinai Medical Center

Central South University

Centro de estudios en Cardiologia Intervencionista

Changhai Hospital

Charles University

Chiangmai University

China Academy of Chinese Medical Sciences

China Medical University

Chinese Academy of Medical Sciences

Chinese Society of Cardiology

Chong Kun Dang Pharmaceutical

Clinical Hospital Center Zemun

Cornell University

Czech Ministry of Education

Daewoong Pharmaceutical Co. LTD.

Daiichi Sankyo

Dalian Medical University

Damanhour University

Dammam Central Hospital

D'Annunzio University of Chieti–Pescara

De Haar Research Foundation

Denver Research Institute

Department of Veteran Affairs

Dong-A Pharmaceutical

Duke University

East Carolina University

Eli Lilly

Emory University

Federal University of Rio Grande do Sul

Forest Laboratories

Fudan University

Fundação de Amparo à Pesquisa do Estado de São Paulo

General Electric

German Federal Ministry of Education and Research

Gilead Sciences

GlaxoSmithKline

Government of China

Government of Czech Republic

Government of Egypt

Government of Israel

Government of Mexico

Government of Taiwan

Guangdong Provincial Hospital of Traditional Chinese Medicine

Guangzhou University

Guerbet

Gyeongsang University

Hallym University

Hanmi Pharmaceutical

Harbin Medical University

Harvard University

Haugaard, Steen Bendix, M.D., DMSc

Heart and Stroke Foundation of Canada

Heart Center of Indianapolis

Hospital Alessandro Manzoni Lecco

Huazhong University of Science and Technology

Humboldt University

Hungarian Academy of Sciences

Icahn School of Medicine at Mount Sinai

Imam Abdulrahman Bin Faisal University

Imperial College London

I.M. Sechenov First Moscow State Medical University

Innogene Kalbiotech Pte. Ltd

Innovaderm

Instituto Mexicano del Seguro Social

Italian Society of Invasive Cardiology

Janssen Pharmaceutica NV

Japan Cardiovascular Research Foundation

Japan Heart Foundation

Jeju National University

Jiangsu Kangyuan Pharmaceutical Co. Ltd

Jiao Tong University

Jikei University

Jilin University

Johannes Gutenburg University

Juntendo University

Kaiser Franz Josef Hospital

Kantonsspital Lucerne

King Fahad Armed Forces Hospital

Kobe University

Korea University

Kos Pharmaceuticals

Kumamoto University

Kyoto Prefectural University of Medicine

Kyoto University

Kyung Hee University

Lantheus Medical Imaging

Laval University

Lepu Medical Technology (Beijing) Co., Ltd.

Liaoning Hospital of Traditional Chinese Medicine

LifeBridge Health

Loyola University

Ludwig Maximilians University

Mayo Clinic

MDS Pharma

Medical College of Wisconsin

Medical University of Graz

Medtronic

Merck

Merck KGaA

Merck Serono

Methodist Cancer Center, Houston, Texas

Monash University

Nanjing Medical University

National Cheng Kung University

National Health and Medical Research Council, Australia

National Heart, Lung, and Blood Institute (NHLBI)

National Institute of General Medical Sciences (NIGMS)

National Natural Science Foundation of China

National Taiwan University

Newcastle University

New York University

Novartis

OBS Pakistan

Ohio State University

Orion Corporation

Osaka University

Otsuka

Pauls Stradins Clinical University Hospital

Peking University

People's Liberation Army of China

Pfizer

Pontificia Universidad Catolica de Chile

Pronova BioPharma

Queen's University, Belfast

Radboud University

Rapid City Regional Hospital

Regeneron

Research Institute for Complex Problems of Cardiovascular Diseases, Russia

Richmond University

Saarland University

Samjin Pharmaceutical Co., Ltd.

Sanatorio Otamendi

Sanofi

Santa Maria University

Schering-Plough

Scott R MacKenzie Foundation

Scripps

Seoul National University

Shanghai Hutchison Pharmaceuticals Limited

Shanghai MicroPort Medical (Group) Co., Ltd.

Shanghai Xuhui District Central Hospital

Shenyang Northern Hospital

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shionogi

Sichuan University

Southeast University

Spanish Society of Cardiology

Stony Brook University

Sungkyunkwan University

Taipei Veteran General hospital

Takeda

Tanta University

Technical University of Munich

Teikyo University

Tel Aviv University

Terumo Corporation

The Alfred Hospital

The Baruch Padeh Medical Center, Poriya

The Methodist Hospital System

The Norwegian Council on Cardiovascular Disease

The University of Hong Kong

The University of Texas, Dallas

Toho University

Tsinghua University

Ukrainian Medical Stomatological Academy

University Hospital of Limerick

University of Barcelona

University of California, Los Angeles

University of California, San Francisco

University of Campania Luigi Vanvitelli

University of Campinas

University of Cologne

University of Copenhagen

University of Dundee

University of Ferrara

University of Florence

University of Florida

University of Geneva

University of Heidelberg

University of Indonesia

University of Iowa

University of Liverpool

University of Ljubljana

University of London

University of Maryland

University of Miami

University of Modena and Reggio Emilia

University of Montreal

University of Oslo

University of Ottawa

University of Oxford

University of Paris

University of Patras

University of Pecs

University of Roma La Sapienza

University of Sao Paulo

University of Texas, San Antonio

University of Turin

University of Ulm

University of Ulsan

University of Vienna

University of Washington

University of Zurich

Uppsala University

Ural Institute of Cardiology

Ural Medical University

Ural State Medical Academy

Vita-Salute University of Milano. Italy

Wake Forest University

WanBangDe Pharmaceutical Group Co.,Ltd.

Washington University in St. Louis

Yamaguchi University

Yokohama City University

Yonsei University

Zuyderland Medisch Centrum

Organization Involved with Phase 3 Indications (187)

Organization Involved with Phase 2 Indications (96)

Organization Involved with Other Experimental Indications (68)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.